AMRN AMARIN CORP PLC\UK
Pharmaceutical Preparations · Nasdaq · SEC CIK 897448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.3%
TTM net income YoY77.8%
TTM EPS YoY81.0%
Revenue 3-yr CAGR-18.3%
Net income 3-yr CAGR—
Margins
Gross margin40.9%
Operating margin-18.2%
Net margin-10.9%
FCF margin—
EBITDA margin—
Returns
ROE-4.2%
ROA-3.0%
ROIC (approx.)-8.1%
Asset turnover0.27x
Leverage & solvency
Liabilities / assets29.9%
Debt / equity0.00x
Current ratio3.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $213.65M | $228.61M |
| Gross profit | $120.87M | $81.38M |
| R&D expense | $19.81M | $20.87M |
| SG&A expense | $115.00M | $152.31M |
| Operating income | -$50.17M | -$91.80M |
| Interest expense | $7,000 | $7,000 |
| Pretax income | -$36.05M | -$77.20M |
| Income tax | $2.75M | $4.98M |
| Net income | -$38.80M | -$82.18M |
| EBITDA | — | -$91.70M |
| EPS (basic) | -0.09 | -0.20 |
| EPS (diluted) | -0.09 | -0.20 |
| Weighted avg. shares (diluted) | 414.98M | 410.94M |
| Balance sheet | ||
| Cash & equivalents | $134.66M | $121.04M |
| Short-term investments | $167.93M | $173.18M |
| Receivables | $126.83M | $122.28M |
| Inventory | $195.91M | $166.05M |
| Current assets | $649.88M | $595.40M |
| PP&E, net | $12,000 | $16,000 |
| Intangibles | $13.37M | $16.39M |
| Total assets | $670.77M | $685.35M |
| Current liabilities | $194.46M | $179.95M |
| Total liabilities | $211.49M | $199.17M |
| Shareholders' equity | $459.28M | $486.18M |
| Shares outstanding | 416.21M | 411.58M |
| Cash flow statement | ||
| Operating cash flow | $6.73M | -$31.02M |
| Investing cash flow | $8.83M | -$45.98M |
| Financing cash flow | -$2.03M | -$1.44M |
| Depreciation & amortization | — | $100,000 |
| Stock-based compensation | $13.94M | $17.70M |
Free plan shows the latest 2 periods; Pro shows all 20 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.